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The RNA-dependent RNA polymerase of hepatitis C virus (HCV) is necessary for the replication of viral
RNA and thus represents an attractive target for drug development. Several structural classes of nonnucleo-
side inhibitors (NNIs) of HCV RNA polymerase have been described, including a promising series of benzo-
thiadiazine compounds that efficiently block replication of HCV subgenomic replicons in tissue culture. In this
work we report the selection of replicons resistant to inhibition by the benzothiadiazine class of NNIs. Four
different single mutations were identified in separate clones, and all four map to the RNA polymerase gene,
validating the polymerase as the antiviral target of inhibition. The mutations (M414T, C451R, G558R, and
H95R) render the HCV replicons resistant to inhibition by benzothiadiazines, though the mutant replicons
remain sensitive to inhibition by other nucleoside and NNIs of the HCV RNA polymerase. Additionally,
cross-resistance studies and synergistic inhibition of the enzyme by combinations of a benzimidazole and a
benzothiadiazine indicate the existence of nonoverlapping binding sites for these two structural classes of
inhibitors.
Hepatitis C virus (HCV) chronically infects about 3% of the
human population, causing a slowly evolving liver disease that
leads to cirrhosis, liver failure, and occasionally hepatocellular
carcinoma (39). Given the size of the HCV epidemic and the
limited efficacy of the present therapy based on alpha inter-
feron (16), the development of new, safer, and more effective
drugs is of paramount importance and is presently an area of
intensive research. The strategy most widely applied for devel-
oping novel anti-HCV therapeutics aims at identifying small
molecule inhibitors of viral enzymes. The nonstructural pro-
tein 5B RNA-dependent RNA polymerase (NS5B RdRp) is an
important target of drug discovery activities largely because it
is essential for viral replication and also due to the clinical
successes of inhibitors of other viral polymerases. In addition,
the extensive structural and biochemical characterization of
this enzyme provides the basis for drug design efforts as well as
for elucidating the mechanism of action of inhibitors and for
rapidly optimizing their potency.
The NS5B protein was initially identified as an RdRp based
on the presence of the signature GDD (Gly-Asp-Asp) motif
characteristic for this class of enzymes (11). Its function was
confirmed when an active form of the full-length protein was
purified from baculovirus-infected insect cells (5). Subse-
quently, attempts to improve solubility, stability, and activity
lead to the expression of C-terminal-truncated forms lacking
the hydrophobic membrane anchor contained within the last
21 amino acids (1, 17, 25, 33, 35). In vitro, the enzyme shows
little, if any, specificity for the HCV genome and can catalyze
the synthesis of RNA by using a variety of homo- or hetero-
polymeric RNA templates both with and without a primer. In
the absence of primer, NS5B can initiate RNA synthesis either
by using the 3-terminal OH group of the template as primer
(5, 25) or by means of an authentic de novo initiation mecha-
nism using a nucleotide complementary to the base at the 3
end of the template as primer (29, 32, 41). It is generally
believed that in infected cells HCV replication is initiated with
a de novo mechanism that guarantees the maintenance of the
genome integrity.
A significant advance in the understanding of the NS5B
polymerase was provided by crystallographic studies of several
truncated forms of the apoenzyme and of complexes with nu-
cleotides or RNA template (1, 2, 6, 7, 24, 31). The NS5B
polymerase has the canonical right-hand shape, with the char-
acteristic fingers, palm, and thumb subdomains. In the crystal,
the apoenzyme and the complexes with nucleoside triphos-
phates (NTPs) or RNA have a closed conformation due to the
presence of two extended loops—the fingertips—that connect
the fingers and thumb domains and completely encircle the
active site cavity. Two structural elements peculiar to the NS5B
polymerase structure are a -hairpin, which protrudes from the
thumb into the active site, and a C-terminal region, located
immediately before the transmembrane domain, that folds
from the surface of the thumb towards the active site and
establishes a series of hydrophobic interactions with a shallow
pocket located between palm and thumb subdomains (1).
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These elements are probably involved in proper positioning of
the 3 terminus of template RNA and are considered crucial
for template selection. Indeed, although the overall conforma-
tion of the enzyme may be maintained during catalysis, local
rearrangements of the -hairpin and of the C-terminal region
seem to be necessary to allow template access and, subse-
quently, to allow the extrusion of the nascent double-stranded
RNA. Biochemical characterizations of deleted enzymes lack-
ing either one of these domains have confirmed that they play
an important role in modulating the initial steps of polymer-
ization (1, 23). Deletion of these elements increased primer-
dependent elongation activity by more than one order of mag-
nitude and had only a minor effect on de novo initiation of
RNA synthesis. These results suggested that the function of
these elements is to discriminate against double-stranded
RNA, thus favoring de novo initiation of RNA synthesis from
the 3 end of single-stranded template. Consistently, superpo-
sition of NS5B structures with and without the C-terminal
extension shows that removal of the C-terminal extension re-
sults in a wider RNA binding cleft and an outward rotation of
the thumb domain (1).
Several inhibitors of the NS5B RdRp have been reported in
the scientific and patent literature that can be classified into
three categories according to their chemical structure and pu-
tative mechanism of action: nucleoside analogues, pyrophos-
phate mimics, and NNIs (12, 13, 37). Among the substrate
analogues, 2-substituted nucleosides act as chain terminators
and effectively inhibit replication of HCV subgenomic repli-
cons (9). The pyrophosphate mimics include two classes of
compounds, dihydroxypyrimidine carboxylic acids and diketo-
acid derivatives, which are believed to inhibit the RdRp activity
through an interaction with the catalytic metal ions in the
enzyme active site (S. Altamura, L. Tomei, J. O. Koch, P. J. S.
Neuner, and V. Summa, 10 February 2000, Published Interna-
tional Patent Application, patent WO 00006529, and C.
Gardelli, C. Giuliano, S. Harper, U. Koch, F. Narjes, J. M.
Ontoria, M. Poma, S. Ponzi, I. Stansfield, and V. Summa, 24
January 2002, Pubished International Patent Application,
patent WO 0206246).
Among the numerous nonnucleoside compounds docu-
mented to have anti-NS5B activity, two series of compounds
have been shown to inhibit the NS5B polymerase allosterically
by binding on the protein surface in a narrow cleft in the thumb
domain (27, 38). In addition, two series of compounds based
on a benzimidazole scaffold (3, 4, 20–22) and a series of ben-
zothiadiazine derivatives (15) have been reported to inhibit
NS5B, with a 50% inhibitory concentration (IC50) below 1 M.
Compounds of both the benzimidazole and the benzothiadia-
zine series were found to effectively inhibit replication of sub-
genomic replicons with no apparent cytotoxicity (14, 18, 34).
Extensive biochemical characterization suggested that benz-
imidazole and benzothiadiazine derivatives inhibited the en-
zyme with an allosteric mechanism. Both classes have been
shown to bind directly the NS5B polymerase and to inhibit
RNA synthesis noncompetitively with respect to NTPs. Single-
turnover experiments indicated that these two classes of com-
pounds blocked the RdRp activity prior to the formation of an
elongation complex (18, 34). Despite these similarities, it is not
clear whether the mechanism of inhibition and/or the site(s)
where these two classes of compounds bind on the enzyme are
similar.
In this work we report an extensive investigation on the
mode of action of benzothiadiazine inhibitors based on a com-
bination of biochemical analysis and characterization of escape
mutants. Several lines of experimental evidence, including
binding studies, kinetic analysis, and cross-resistance studies,
indicate that benzothiadiazine compounds inhibit the enzyme
by interacting with a site distinct from that of benzimidazole
analogues.
MATERIALS AND METHODS
Inhibitors. Compound 1 [1-butyl-3-(1,1-dioxido-2H-1,2,4-benzothiadiazin-3-
yl)-4-hydroxyquinolin-2(1H)-one] was purchased from Interbioscreen (Moscow,
Russia), and compound 2 [3-(1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-
1-isobutylquinolin-2(1H)-one] was purchased from Asinex (Moscow, Russia). Com-
pound A (2-[4-({4-chloro-4-[(4-hydroxypiperidin-1-yl) carbonyl]-1,1-biphenyl-2-
yl}methoxy)-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid)
and compound B (N-{[1-cyclohexyl-2-(3-furyl)-1H-benzimidazol-5-yl]carbonyl}-
5-hydroxy-L-tryptophan) were synthesized as described previously (3, 21).
Plasmids. Plasmid pHCVNeo17.B (36) encodes an HCV replicon identical to
I377neo/NS3-3/wt (26) (EMBL-GenBank No. AJ242652) but containing two
tissue culture-adaptive mutations, namely replacement of triplet GAA (nucleo-
tides [nt] 2329 to 2331), coding for glutamic acid 176 in NS3, with GGA, coding
for glycine, and insertion of an extra AAA triplet (coding for lysine) after the
triplet GTG (nt 4840 to 4842), coding for valine 67 in NS5A. All other replicon
plasmids are derived from pHCVNeo17.B and contain the following mutations:
pHCVNeo17.BR3, replacement of triplet CAT (nt 7882 to 7884), coding for
histidine 95 in NS5B, with triplet CGT (coding for arginine); plasmid
pHCVNeo17.BR4, replacement of the triplet ATG (nt 8839 to 8841), coding for
methionine 414 in NS5B, with ACG (coding for threonine); plasmid
pHCVNeo17.BR5, replacement of triplet TCT (nt 8951 to 8953), coding for
cysteine 451 in NS5B, with triplet CGT (coding for arginine); plasmid
pHCVNeo17.BR6, replacement of triplet GGA (nt 9271 to 9273), coding for
glycine 558 in NS5B, with triplet AGA (coding for arginine); plasmid
pHCVNeo18.B, replacement of triplet GAG (nt 2096 of the neomycin phospho-
transferase gene), coding for glutamate 182, with triplet TAG (coding for aspar-
tate) (40). Plasmid pT7-NS5BC21 contains the HCV-BK sequence coding for
NS5B protein lacking the 21 C-terminal residues (retaining residues 1 to 570) in
the pT7-7 expression vector (8). pT7-NS5BC55 codes for NS5B protein lacking
55 C-terminal residues (retaining residues 1 to 536) (35). pT7-NS5BC21-
Loop codes for a NS5BC21 carrying a deletion of residues C445 to Y452 and
substitutions D444G and S453G. Plasmids pT7-NS5BC21-H95R, pT7-
NS5BC21-M414T, pT7-NS5BC21-C451R, and pT7-NS5BC21-G558R con-
tain the same point mutations indicated in the corresponding replicon plasmids.
NS5B expression and purification. Expression in Escherichia coli BL21(DE3)
and purification of the HCV NS5B proteins were carried out as described
previously (9).
Polymerase assays. Primer elongation reactions were carried out in 50 l of a
solution of 20 mM Tris-HCl [pH 7.5], 0.01% Triton X-100, 10 mM NaCl, 1 mM
dithiothreitol, 0.1 g of bovine serum albumin/l, 2 mM MgCl2, 10 M UTP, 2
Ci of 3H-UTP (47 Ci/mmol; Amersham), 20 nM purified NS5B, and 0.5 M
poly(A)  oligo(U)18. Compounds were dissolved in 100% dimethyl sulfoxide
(DMSO), and serial dilutions were made in DMSO. Unless otherwise specified,
compounds, polymerase, and template RNA were incubated at room tempera-
ture for 60 min before the addition of NTPs. Elongation reactions were allowed
to proceed for 30 min at RT, and the activity was measured as the radioactivity
present in the acid-insoluble material.
De novo assays were performed in 50 l of a solution of 15 mM Tris [pH 7],
20 mM MgCl2, 0.05% Triton X-100, 10 g of BSA/ml, 1 mM DTT, 6 M
3H-GTP (2  106 cpm; 7.8 Ci/mmol; Amersham), 2 mM GMP, 50 nM poly(C)
(50-mer), and 50 nM HCV NS5BC21 enzyme. The enzyme was preincubated in
reaction buffer at room temperature for 15 min with the compound and template
RNA. The reaction was started by the addition of the 3H-GTP and GMP mixture
and was incubated at room temperature for 60 min. The RNA products were
precipitated by addition of 50 l of 20% trichloroacetic acid (TCA), filtered on
GF/B filter plates, and read by a Top Count liquid scintillation counter (Pack-
ard).
IC50 values were calculated by using a three-parameter logistic equation, and
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inhibition data were fitted by using Kaleidagraph software (Synergy Software,
Reading, Pa.).
Kinetic parameters were calculated from a least-square fit of initial rates as a
function of substrate concentration assuming Michaelis-Menten kinetics.
Polymerase-inhibitor interaction. The polymerase-inhibitor complex was
monitored essentially as already described (34). Polymerase (10 M) and com-
pound (10 M) were mixed in 60 l of incubation buffer containing 20 mM
Tris-HCl (pH 7.5), 3 mM DTT, 100 mM NaCl, 0.03% n-octyl glucoside, 10%
glycerol, 0.01% DMSO, 15 M poly(A)  oligo(U)18. Following 30 min of incu-
bation at room temperature the mixture was applied to a gel filtration G-25 spin
column (Pharmacia) prewashed with the incubation buffer lacking the RNA. The
eluate, containing the protein-inhibitor complex and the free protein, was recov-
ered by centrifugation for 2 min at 1,450  g. The eluting protein was quantified
by Bradford assay (Bio-Rad), while the presence of the inhibitor was assessed by
mass spectrometry, as described previously (34).
Tissue culture, replication analysis, selection, and sequencing of resistant
replicons. Huh-7, HBI10A, and NM15 cells were cultured and transfected by
electroporation with in vitro-transcribed RNAs as previously described (36).
NM15 cells were obtained by G418 selection of Huh-7 cells transfected with
replicon pHCVNeo18.B, a modified replicon with a point mutation in the neo-
mycin phosphotransferase protein that renders the enzyme less active, resulting
in a tighter correlation between G418 resistance and replication level (L. Bar-
tholomew, A. Cellucci, and G. Migliaccio, unpublished data). Transient trans-
fection assays were performed by using cells highly competent for HCV replica-
tion, obtained by curing HBI10A cells of the endogenous replicons with human
interferon-2b as described previously (36). The effect of compounds on viral
replication was monitored by Cell-enzyme-linked immunosorbent assay (ELISA)
(36). Clones resistant to compounds 1 and 2 were selected as described previ-
ously (36). NM15 cells were plated in 15-cm-diameter tissue culture dishes at a
density of 3  103/cm2 and were cultured in the presence of 0.8 mg of G418/ml
and increasing concentrations of compounds. Approximately 15 days after be-
ginning selection, small colonies of cells resistant to the inhibitor and the anti-
biotic became visible and were isolated. Replicon RNAs extracted from resistant
clones were retrotranscribed and amplified by PCR, and their sequence was
determined by direct automated sequencing of the PCR products (36).
RESULTS
Biochemical characterization of benzothiadiazine inhibi-
tors. NNIs of the NS5B polymerase based on a benzothiadia-
zine scaffold have been described in the scientific and patent
literature (14, 15, 18). Based on a benzimidazole structure,
benzothiadiazines inhibit the NS5B polymerase activity prior
to the RNA elongation phase of the reaction in a manner
similar to that of other NNI. To gain a better understanding of
the mechanism of inhibition of this series, we selected two
representative compounds and studied details of the inhibition
of several enzyme variants by using different assay methods.
Effect of template RNA. Benzothiadiazines have been re-
ported to inhibit the NS5B polymerase with a mechanism that
is noncompetitive with NTPs or RNA (14, 18). Changing the
order of assay reagents did not affect inhibitor potency (18).
However, by changing the order of reagent addition in the
polymerase reaction, we observed that template RNA influ-
enced the ability of compounds 1 (data not shown) and 2 (Fig.
1A) to cause complete inhibition of the C21 enzyme activity.
When inhibitors were added to the reaction prior to or together
with the RNA template, complete inhibition was gradually
reached at concentrations above 20 M. Conversely, when the
enzyme was preincubated with the poly(A)  oligo(U)18 tem-
plate prior to inhibitor addition, inhibition curves were altered
and a significant fraction of the polymerase activity was not
inhibited even at very high compound concentrations (Fig.
1A). Similar results were obtained with the heteromeric RNA
template t500 (8) (data not shown). In agreement with previ-
ous results (18), the IC50 for the inhibited fraction of the
enzyme activity was not significantly changed by the preincu-
bation with template. These observations were confirmed by
varying the time of the preincubation of the RNA template and
enzyme (Fig. 1B). The polymerase activity resistant to inhibi-
tion by 15 M compound 1 or compound 2 increased as a
FIG. 1. Effect of template RNA. (A) Order of addition. Increasing
amounts of compound 2 (20 nM to 20 M) were added to polymerase
and to poly(A)  oligo(U)18 RNA that were (F) or were not (}) pre-
incubated 20 min at room temperature. (B) Preincubation time course.
The NS5BC21 and the poly(A)  oligo(U)18 RNA were preincubated
from 0 to 120 min before the addition of 15 M compound 1 (}) or 2
(F). (C) Effect of preincubation of template RNA and enzyme on
enzyme activity. Polymerase activity is reported as the radioactivity
incorporated in the absence of inhibitor compounds with increasing
time of preincubation of enzyme and RNA.
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function of enzyme-template preincubation time, suggesting
that preincubation with template partially protected the en-
zyme from inhibition by both inhibitors. Enzyme activity in the
absence of inhibitor also increased as preincubation time in-
creased (Fig. 1C). In these experiments the inhibited fraction
of the activity that remains after longer preincubations of en-
zyme and template likely results from those polymerase mol-
ecules that dissociated from the template during the reaction
and were thus susceptible to inhibition. Indeed, in agreement
with previous results (18), we could confirm that in the pres-
ence of heparin as a trapping reagent for free enzyme, prein-
cubation with template completely protected the enzyme from
inhibition (data not shown).
Activity on different enzyme forms. To further investigate
the mechanism of inhibition of this series, we tested each
inhibitor on different forms of the polymerase. Remarkably,
compared to inhibition of the C21 enzyme form, the inhibi-
tors displayed at least one order of magnitude-reduced inhib-
itory potency with truncated enzymes lacking either the C-
terminal 34 residues of the C21 enzyme form (C55) or the
-hairpin (Loop), indicating that these elements were crucial
for the inhibitory activity of benzothiadiazines (Table 1).
Selection and characterization of resistant mutants. The
effect of compounds 1 and 2 on the replication of HCV sub-
genomic replicons was confirmed by using replicon clones
HBI10A and NM15 and by monitoring expression of the NS3
protein by Cell-ELISA (36). Incubation of either clone with
compounds 1 and 2 resulted in a dose-dependent reduction of
the level of NS3 protein with IC50 values comparable to those
reported previously (Table 2) (14). Similar results were ob-
tained when viral replication was measured by monitoring ex-
pression of viral RNA by in situ RNase protection (data not
shown) (9). Cytotoxicity assays and [14C]thymidine incorpora-
tion experiments showed that compounds 1 and 2 were not
toxic and had no effect on cellular growth rate at concentra-
tions up to 50 M (data not shown), thus indicating that the
decreased expression of viral RNA and proteins reflected a
direct effect on viral replication.
To obtain definitive evidence of the link between enzyme
inhibition and antiviral effect, we selected and characterized
replicons resistant to compounds 1 and 2 by adopting a strategy
already used for selecting mutants resistant to other replication
inhibitors (30, 34, 36). Cell clones resistant to both compounds
were obtained by culturing NM15 cells in the presence of G418
and either compound at concentrations increasing from 4- to
10-fold (compound 2) or 4- to 20-fold (compound 1) higher
than their respective IC50. Resistance selection experiments
yielded several clones resistant to both compounds 1 and 2 that
maintained the same rate of cell doubling as the parental cells
and expressed HCV RNA and proteins at comparable levels
(data not shown). Independently of the compound used for
selection, replication of the cognate replicons was resistant to
both inhibitors: selected clones displayed IC50 values more
than fivefold higher than those of parental cells (Table 2).
Unexpectedly, incubation of cells with compounds 1 and 2
increased in a dose-dependent fashion the expression of the
NS3 protein in clones P17 and P20 but not in the other clones,
suggesting that the compounds activated rather than inhibited
replication of the cognate replicons (data not shown). These
clones were still sensitive to inhibition by alpha interferon (19),
the nucleoside inhibitor 2-C-methyl-adenosine (9), and the
benzimidazole-based nonnucleoside inhibitor compound A
(34), demonstrating that resistance was specific for benzothia-
diazine-based compounds (Table 2 and data not shown). Cor-
respondingly, replicon clones selected with 2-C-methyl-aden-
osine and with compound A remained sensitive to inhibition by
the two benzothiadiazine inhibitors (9, 34 and data not shown).
To ascertain whether resistance was due to replicon muta-
tions, we determined the sequences of the NS5B coding region
of replicons extracted from resistant clones and compared
them to that of replicons extracted from parental NM15 cells
(Table 2). Remarkably, all replicons derived from resistant
TABLE 1. Structure and activity of benzothiadiazine compounds on
different forms of the NS5B polymerase
Compound Structure
IC50 (M) for:
C21 C55 C21-Loop
1 0.2  0.1 4.5  1.0 		4
2 0.3  0.1 		4 		4
TABLE 2. Effect of replication inhibitors on parental and benzothiadiazine-resistant replicon clones
Clonea NS5B mutation
IC50 (M) as determined by Cell-ELISAb
Compound 1 Compound 2 Compound A 2-C-methyl-adenosine
HB110A 3.2  1.1 9.8  3 0.35  0.05 0.32  0.1
NM15 4.7  1.6 11.4  3.6 0.63  0.22 0.39  0.15
P2 H95R 	20 	50 0.28  0.04 0.38  0.08
P6 M414T 	20 	50 0.25  0.16 0.51  0.11
P13 H95R 	20 	50 Not tested Not tested
P17 C451R 	20 	50 0.13  0.02 0.29  0.12
P20 G558R 	20 	50 0.2  0.12 0.28  0.12
Q13 H95R 	20 	50 0.23  0.11 0.38  0.15
Q14 H95R 	20 	50 0.24  0.1 0.75  0.3
a P clones were selected with compound 1, and Q clones were selected with compound 2.
b Data are average of at least duplicate determinations.
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clones contained a single amino acid mutation in the NS5B
polymerase. Four clones (P2, P13, Q13, and Q14) contained
replacement of histidine 95 with arginine (H95R), while mu-
tations in the other clones were different and included the
following replacements: methionine 414 with threonine
(M414T), cysteine 451 with arginine (C451R), and glycine 558
with arginine (G558R).
The role of these mutations was investigated by segregating
them in a replicon vector containing the adaptive mutations
present in the parental replicon (36) and testing the resulting
replicons in transient transfection assays. As expected, the pa-
rental replicon (B) was inhibited by both compounds with IC50
values comparable to those observed for HBI10A and NM15
cells (Table 3). In contrast, replicons containing NS5B substi-
tutions H95R and M414T replicated at levels comparable to
the control replicon and were clearly resistant to both com-
pounds. The IC50 values measured for these replicons were
similar to those observed in the resistant cells, indicating that
each of the tested substitutions was by itself sufficient to reca-
pitulate the resistance phenotype displayed by the correspond-
ing clones. Consistent with the results obtained with clones P17
and P20, the replicons containing the C451R or the G558R
mutation replicated to low or undetectable levels in the ab-
sence of compounds, respectively, but their replication was
stimulated in a dose-dependent fashion by both compounds 1
and 2. At high compound concentrations replication was com-
parable to that of the control replicon (Fig. 2). A much less
pronounced activation was also observed with the H95R mu-
tant replicon (data not shown). As expected, the replicons
containing NS5B substitutions H95R, M414T, and C451R re-
mained sensitive to inhibition by the benzimidazole-based in-
hibitor compound A, confirming that these mutations were
specifically responsible for resistance to benzothiadiazine in-
hibitors (Table 3). The effect of compound 1 on the G558R
replicon could not be estimated because of the inefficient rep-
lication of this mutant in the absence of benzothiadiazine com-
pounds.
Characterization of mutant polymerases. To confirm that
the above mutations were sufficient for resistance, we ex-
pressed and purified recombinant C21 polymerases contain-
ing the H95R, M414T, C451R, and G558R mutations and
compared them to the wild-type C21 enzyme. All the mutant
polymerases displayed catalytic efficiencies greater than that of
the wild-type enzyme both in the primer elongation (Table 4)
and in the de novo reaction (data not shown). The increased
catalytic efficiency in each case was primarily the result of an
increase in kcat, because Km values for NTP and for the RNA
template were unchanged (Table 4). Unexpectedly, the puri-
fied mutant polymerases exhibited different responses to inhi-
bition depending on the individual mutation. While the M414T
mutation conferred a reduced susceptibility to inhibition by
both compound 1 and 2 (and was therefore confirmed as suf-
ficient for resistance to both inhibitors), the H95R substitution
did not protect the purified enzyme against inhibition. More-
over, the protective effect of both C451R and G558R muta-
tions was marginal and was mainly evident in de novo assays.
Interestingly, in the de novo reaction both compounds 1 and 2
inhibited the wild-type C21 polymerase with IC50 values 5- to
10-fold lower than those measured in the primer elongation
assay.
To further investigate the mechanism of resistance we uti-
lized a direct binding assay based on separation of the poly-
merase-inhibitor complex from the unbound inhibitor by gel
filtration chromatography. In agreement with previous results
FIG. 2. Benzothiadiazine compounds stimulate replication of C451R and G558R mutant replicons. 10AIFN cells were transfected with control
(white), C451R (gray), and G558R (black) replicons and were cultured in the absence or in the presence of the indicated concentrations of either
compound 1 (A) or compound 2 (B). HCV replication was monitored by cell-ELISA as indicated in Materials and Methods.
TABLE 3. Replication efficiency and sensitivity to inhibitors of mutant pHCVNEO17 replicons
Clone NS5Bmutation
Replication
efficiencya
IC50 (M) for:
Compound 1 Compound 2 Compound A
B 19 1.9  0.4 11.5  1 0.37
R3 H95R 17.9 	20 	50 0.2
R4 M414T 12 	20 	50 0.32
R5 C451R 5–18b 	20b 	50b 0.1
R6 G558R 2–15b 	20b 	50b NAc
a Replication efficiency and replicon IC50 were determined by Cell-ELISA. Replication efficiency is expressed in arbitrary units.
b Replication efficiency increased in the presence of compounds in a dose-dependent fashion (see Fig. 3).
c NA, not applicable.
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(14), this assay confirmed that compound 1 bound the C21
enzyme both in the absence and in the presence of template
RNA (Table 5). In line with the reduced inhibitory potency
measured in activity assays, binding of compound 1 to the
C55 form of the polymerase was not observed. As expected
on the basis of the significant decrease of inhibition efficacy,
mutant M414T was unable to interact with the compound both
in the absence and in the presence of RNA (Table 5). In
contrast, interaction of compound 1 with the H95R, C451R,
and G558R mutants was still observed, partially explaining the
modest effect of these substitutions on inhibitor potency and
the enhancement of replication of mutant replicons, which
suggests that these mutations do not abolish inhibitor binding
capability. Due to the low solubility of compound 1 in aqueous
buffers, the compound eluted with the each mutant enzyme
could not be estimated with accuracy sufficient to evaluate
binding stoichiometry. Nevertheless, the differences measured
by liquid chromatography-mass spectrometry analysis were of
amplitudes sufficient to permit an unequivocal evaluation of
the binding ability of the different mutant enzymes (data not
shown).
Synergistic inhibition. The potential for synergistic inhibi-
tion of enzyme activity by combinations of nonnucleoside in-
hibitors was assessed in enzyme-catalyzed kinetic reactions. As
shown in Fig. 3, synergistic inhibition of the wild-type enzyme
is evident in reaction mixtures containing combinations of a
benzimidazole (compound B) and a benzothiadiazine (com-
pound 1), as demonstrated by the nonparallel lines in the
Yonetani-Theorell plots. Synergistic inhibition of enzyme ac-
tivity can result from the simultaneous binding of two inhibi-
tors and occurs in reactions measuring either primer-depen-
dent (data not shown) or de novo RNA synthesis (Fig. 3). The
possibility of simultaneous binding of the two compounds was
further verified by binding competition experiments using com-
pound 1 and a saturating concentration of compound B (100
M). The experiment was performed only in the presence of
RNA because of the inability of compound B to interact with
the enzyme in the absence of RNA (34). Binding of compound
1 to the C21 enzyme was still observed even in the presence
of high molar excess of compound B, further strengthening the
conclusion that the two compounds bind the enzyme at differ-
ent sites (Table 5).
DISCUSSION
The identification of several structural classes of NNIs of
HCV NS5B polymerase that are active in the cell-based rep-
licon assay has previously been disclosed (3, 14, 21, 27, 38).
Representative compounds from these structural classes have
been shown to be noncompetitive with the NTP substrate,
FIG. 3. Synergistic inhibition of polymerase activity by combina-
tions of a benzothiadiazine and a benzimidazole. Inhibition by the
benzimidazole, compound B, of the catalytic activity of C21 in assays
following de novo initiation of synthesis was determined in the absence
(E) or the presence of 0.015 (F), 0.03 (), or 0.06 () M compound
1. Data are plotted as the ratio of reaction rates in the absence (v0) and
in the presence (vi) of inhibitor(s). The nonparallel best-fit lines indi-
cate synergistic inhibition by the combination of inhibitors. A similar
pattern of lines was evident for inhibition of primer-dependent assays
of polymerase activity in the presence of combinations of compound 1
and compound B.
TABLE 4. Catalytic efficiency and sensitivity to benzothiadiazine compounds of mutant enzymes
Protein Km UTP (M) Km RNAa (nM) kcat (min
1)
IC50 (M) of compound in:
Primer elongation de novo reaction
Compound 1 Compound 2 Compound 1 Compound 2
C21 10.8  2 32  6 0.43  0.03 0.2  0.1 0.3  0.1 0.017  0.02 0.06  0.03
C21-H95R 10  1.5 25  5 2.8  0.60 0.04  0.01 0.035  0.02 0.018  0.02 0.085  0.04
C21-M414T 8.3  0.7 35  3 1.85  0.25 2.2  0.3 5.9  0.8 1  0.02 3  0.05
C21-C451R 11.3  1.3 44  8 6.2  0.10 0.05  0.02 1  0.05 0.1  0.02 0.2  0.02
C21-G558R 11.6  1.3 45  3 5.15  0.15 0.27  0.03 0.95  0.09 0.1  0.01 0.5  0.03
a RNA is poly(A)  oligo(U)18.
TABLE 5. Binding capability of compound 1 to wild-type
and mutant polymerases
Protein Compound 1binding
C55 ................................................................................................. 

C55a................................................................................................ 

C21 ................................................................................................. 
C21a................................................................................................ 
C21-M414T.................................................................................... 

C21-M414Ta ..................................................................................

C21-C451R ....................................................................................
C21-C451Ra...................................................................................
C21-G558R....................................................................................
C21-G558Ra ..................................................................................
C21-H95R......................................................................................
C21-H95Ra ....................................................................................
C21  compound Ba....................................................................
a Protein plus poly(A)  oligo(U)18.
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suggesting that their binding site(s) on the polymerase does not
overlap the enzyme active site. Indeed, crystallographic data
establish that the binding site of two classes of NNIs, phenyl-
alanine derivatives and a dihydropyranone, lies at the base of
the thumb region of the polymerase distal to the active site (28,
38). Additionally, substitution of proline 495 of NS5B polymer-
ase with leucine or alanine (P495L/A) renders both the enzyme
and the corresponding replicon resistant to inhibition by a
third class of NNI based on a benzimidazole scaffold, support-
ing the existence of another binding site for this class of com-
pounds (34). In this paper the mode of action of benzothia-
dizine inhibitors and their binding site on the HCV polymerase
were explored by a combination of biochemical and genetic
analyses, with particular emphasis on the comparison with ben-
zimidazole-based inhibitors.
Basic similarities exist in the mechanism of inhibition by
benzothiadiazine and benzimidazole compounds. Experiments
to determine the mechanism of inhibition have indicated that
benzimidazoles (34) and benzothiadiazines (18) inhibit the en-
zyme prior to the elongation phase of the reaction. In addition,
results presented in this and in previous work (34) indicated
that the activity of both classes of inhibitors is affected by the
presence of the template RNA. Indeed, as in the case of
benzimidazoles, enzyme activity resistant to benzothiadiazines
increased as the time of preincubation of enzyme and template
increased, suggesting that the binding of the template pro-
tected the enzyme from inhibition in the absence of catalysis
and that this protection occurred relatively slowly. Enzyme
activity also increased as a result of the preincubation with
template, suggesting that the protection against inhibition and
increase in activity may have resulted from the same or a
related change. However, binding of the template does not
prevent benzimidazoles (34) or benzothiadiazines from bind-
ing to the enzyme, as shown in the direct compound binding
experiments. Thus, the model that emerges from these data are
one where template or inhibitor binding influences the distri-
bution of enzyme between an active and an inactive enzyme
conformation, that this conformational change occurs slowly
and prior to NTP binding and catalysis.
However, several differences in the inhibition by benzimida-
zoles and benzothiadiazines are apparent. Benzimidazoles are
equally effective inhibitors of the C55 and C21 forms of the
enzyme, whereas benzothiadiazines are much more potent in-
hibitors of the C21 polymerase. In addition, synergistic inhi-
bition by their combination, highlighted by the nonparallel
lines in the Yonetani-Theorell plot, and the lack of competi-
tion in the direct binding experiment indicate the ability of
both inhibitors to bind simultaneously to the enzyme, support-
ing the existence of separate binding sites. Moreover, increas-
ing concentrations of GTP abrogate inhibition by benzimida-
zoles (34) but do not have the same effect on the inhibition by
benzothiadiazines. Lastly, the resistance substitutions for the
two classes of compounds are different, providing additional
evidence that they do not interact with the enzyme at the same
site.
Replicons resistant to inhibition by benzothiadiazines were
selected in the presence of compound and the mutations were
mapped to the polymerase, genetically validating the target of
benzothiadiazines. Four different single mutations were iden-
tified that lie in different regions of the enzyme (Fig. 4). M414T
is in an alpha-helical region of the thumb domain, with its side
chain directed into the active site. C451R is in the -hairpin;
H95R is in the fingers and may interact with the bound tem-
plate; G558R is close to the C-terminal end of the C21
enzyme. The fact that individual mutations located in different
regions of the enzyme give rise to resistance suggests there may
be multiple mechanisms for resistance. This interpretation is
reinforced by the observation that the replicons containing
each of these mutations display different replication and resis-
tance phenotypes and that the corresponding recombinant
polymerases show different degrees of sensitivity to the inhib-
itors.
Replicons containing M414T and H95R showed a similar
efficiency of replication compared to that of the wild type and
were completely resistant to inhibition by benzothiadiazines.
Surprisingly, replicons containing C451R and G558R showed
significant levels of replication only in the presence of benzo-
thiadiazines, suggesting that within the context of the replica-
tion complex the active conformation of the polymerase was
achieved only in the presence of the compound.
Biochemical data from studies of the purified M414T mu-
tant enzyme demonstrate that it is 50-fold more resistant to
inhibition by either benzothiadiazine in the assay measuring
RNA synthesis following de novo initiation. These results bio-
chemically confirm the target of the inhibition and suggest that
the primary mechanism of resistance of M414T is a reduction
in the binding affinity of the benzothiadiazines. This interpre-
tation was confirmed by assays assessing the direct binding of
the compound to the M414T mutant enzyme that indirectly
suggest that methionine 414 is part of the binding site for
benzothiadiazine compounds. Additionally, the M414T poly-
merase displays an increased catalytic efficiency compared to
that of the wild-type enzyme, as do the other resistant mutants
FIG. 4. Position of the sites of resistance mutations within the
structure of C21 polymerase. The fingers region of the enzyme is
shown in red, the palm in green, and the thumb in blue. The -hairpin
is shown in orange. The metal ions that are required for activity are
represented by the gray spheres. The 34-residue C-terminal region of
the C21 enzyme form is colored in gray. The side chains of amino
acids H95 (yellow), M414 (red), C451 (green), and G558 (orange) are
also shown. The structural coordinates are from Lesburg et al. (24).
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in this study. Since neither Km for NTPs nor for the RNA
template is significantly different for the mutants than it is for
the wild-type enzyme, the increased catalytic efficiency of these
mutants could be due to a higher amount of active protein that
can productively interact with RNA and/or to a faster rate of
the conformational change leading to a productive polymer-
ase-RNA complex.
At variance with the M414T polymerase, the enzymes con-
taining the other three resistance mutations show a complex
pattern of sensitivity to the benzothiadiazine inhibitors. The
enzymes containing either the C451R or the G558R mutations
were not clearly resistant to inhibition in the primer elongation
assay but showed a moderate level of resistance in the de novo
assay. The location of these mutations in the -hairpin (C451R)
and C-terminal region near the -hairpin (G558R) is consis-
tent with the results of deletion mutants that demonstrate that
these regions are important determinants for inhibition by
benzothiadiazines. Both mutations might have a role in mod-
ulating the movement of the -hairpin and/or C-terminal re-
gion in a way that leads to decreased inhibition by benzothia-
diazines as well as increased catalytic activity. This altered
movement or position of the -hairpin/C-terminal region might
explain why replicons containing C451R or G558R do not
replicate efficiently in the absence of compound. Replicons
containing NS5B with the -hairpin deleted also replicate
poorly, though the corresponding enzyme is more active than
the wild-type enzyme in both primer-dependent and de novo
initiation assays (10). The higher inhibitory potency, together
with the more obvious effect of resistance mutations, in the de
novo rather than in primer elongation assays, might indicate
the de novo initiation of RNA synthesis as the primary target
of inhibition by benzothiadiazine compounds.
Surprisingly, the H95R mutant enzyme was as sensitive or
more sensitive than the wild type to inhibition by benzothia-
diazines, making it difficult to rationalize the resistant pheno-
type observed with the corresponding mutant replicon. It is
conceivable that some of the functions of the HCV polymerase
in the replication complex, such as specific recognition of the
viral genome and interaction with other factors which might
modulate its activities, are not entirely reproduced in the in
vitro assays, thus limiting the biochemical dissection of the
mutations’ effect.
Interestingly, alignment of the sequences of full-length HCV
genomes available in the public databases revealed a different
degree of conservation of the NS5B residues involved in resis-
tance to benzothiadiazine inhibitors. In fact, while histidine 95
and glycine 558 are highly conserved (	99% and 96%, respec-
tively), the other two residues are much more variable. The
amino acid at position 414 is methionine in 86% of the natural
isolates and is replaced by glutamine in genotype 2 isolates.
The amino acid at position 451 is even less conserved and is
cysteine only in 52% of the natural viruses and is replaced by
valine in genotype 2 isolates and threonine, isoleucine, ty-
rosine, or histidine in viruses belonging to other genotypes.
Although the effects of these natural variations on the activity
of benzothiadiazine compounds have not been investigated,
their occurrence suggests that some HCV isolates might be
resistant to this class of inhibitors.
The discovery of NNIs of HCV RNA polymerase that are
active in the cell-based replicon assay has created the possibil-
ity of developing direct inhibitors of polymerase activity as
therapies for HCV infection. A greater understanding of the
mechanism of inhibition would assist in the design of more
potent compounds with the required pharmacokinetic and
safety parameters to justify clinical investigation of their effi-
cacy.
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